Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

AIDS

Volumn 14, Issue 4, 2000, Pages

  Tebas, Pablo ^a   Powderly, William G ^a   Claxton, Sherry ^a   Marin, Donna ^a   Tantisiriwat, Woraphot ^a   Teitelbaum, Steven L ^a   Yarasheski, Kevin E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiposity; Aspartyl protease inhibitors; Bone densitometry; Bone mineral metabolism; HIV infection; Osteoporosis

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BONE ATROPHY; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 0034031191     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00005     Document Type: Article

References (24)

1. 1. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. 2. Anonymous. Update: trends in AIDS incidence - United States, 1996. MMWR 1997, 46:861-867.
3. 3. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997, 127:947.
4. 4. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997, 127:948.
5. 5. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998, 351:867-870.
6. 6. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
7. 7. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
8. 8. Carr A, Samaras K, Thorisdottir A, Kaufmann CR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093-2099.
9. 9. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
10. 10. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.
11. 11. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999, 21:209-216.
12. 12. Meyer D, Behrens C, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999, 13:1147-1148.
13. 13. Manzaneque Gonzalez L, Mayoral Martin L, Jimenez Ocana C, Corzo Delgado JE, Sanchez-Matas Rodriguez P, Grilo Reina A. Bilateral avascular necrosis of the femur head in an HIV-positive male. Anales de Medicina Interna 1994, 11:601-603.
14. 14. Gibert C, Koller E, Mann M, Bacsanyi J, Malozowski S. Avascular necrosis in AIDS patients receiving megestrol acetate. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago. 1998 [abstract 478].
15. 15. De Truchis P, Saillour M, Pigne E, et al. Avascular necrosis of bone in HIV-infected patients with antiphospholipid antibodies. XI International Conference on AIDS. Vancouver, 1996 [abstract MoB1298].
16. 16. Stovall D, Jr., Young TR. Avascular necrosis of the medial femoral condyle in HIV-infected patients. Am J Orthop 1995, 24:71-73.
17. 17. Gerster JC, Camus JP, Chave JP, Koeger AC, Rappoport G. Multiple site avascular necrosis in HIV infected patients. J Rheumatol 1991, 18:300-302.
18. 18. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting [published erratum appears in J Clin Endocrinol Metab 1997 82:3360]. J Clin Endocrinol Metab 1997, 82:1332-1337.
19. 19. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997, 7:390-406.
20. 20. Nevitt MC, Johnell O, Black DM, Ensrud K, Genant HK, Cummings SR. Bone mineral density predicts non-spine fractures in very elderly women. The Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994, 4:325-331.
21. 21. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group [see comments]. Lancet 1993, 341:72-75.
22. 22. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919-23.
23. 23. Paton NIJ, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997, 61:30-32.
24. 24. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145-150.